Gemini Therapeutics (NASDAQ:GMTX) Trading Down 1.3% – Time to Sell?

Shares of Gemini Therapeutics, Inc. (NASDAQ:GMTX) traded down 1.3% during mid-day trading on Thursday . The stock traded as low as $72.86 and last traded at $73.67. 358,388 shares changed hands during trading, an increase of 89% from the average session volume of 189,291 shares. The stock had previously closed at $74.65.

Gemini Therapeutics Price Performance

The firm has a market cap of $3.19 billion, a PE ratio of -73.67 and a beta of -0.12. The business has a 50-day moving average price of $72.26 and a two-hundred day moving average price of $69.62.

Gemini Therapeutics Company Profile

Gemini Therapeutics (NASDAQ:GMTX) is a clinical‐stage biotechnology company focused on the discovery and development of integrin‐targeting therapies for fibrotic diseases. Leveraging a proprietary antibody discovery platform, Gemini identifies and optimizes highly selective inhibitors of integrin subunits that play a key role in activating transforming growth factor‐β (TGF-β), a central driver of tissue fibrosis. The company’s approach is designed to block fibrotic signaling at its source, potentially offering improved safety and efficacy profiles compared with broader anti‐fibrotic agents.

Gemini’s lead programs are directed toward chronic kidney disease and idiopathic pulmonary fibrosis, two areas with significant unmet medical need and limited treatment options.